Virpax Pharmaceuticals, Inc.
We are a preclinical stage biopharmaceutical company focused on becoming a global leader in pain management by developing and delivering innovative non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. We are developing branded pharmaceutical product candidates for pain management by using advanced technology in an effort to enhance patients’ quality of life.
We have exclusive global rights to develop, sell and export (among other rights) a proprietary patented non-steroid anti-inflammatory Topical Spray Film Delivery Technology (described as a pain “patch in a can”) for acute musculoskeletal pain (“DSF100” or “EpoladermTM”) and chronic osteoarthritis of the knee (“OSF200”). We also have exclusive global rights to a proprietary patented injectable, long-acting “local anesthetic” Liposomal (Hydro) Gel Technology for postoperative pain management (“LBL100” or “ProbudurTM”). Additionally, we have exclusive global rights to a proprietary patented Molecular Envelope Technology (“MET”) that uses an intranasal device to deliver exogenous enkephalin for the management of acute and chronic pain, including pain associated with cancer, (“NES100” or “EnveltaTM”) and for the management of Post-Traumatic Stress Disorder (“PES200”). Enkephalins are pain-relieving pentapeptides produced in the body, and function to inhibit neurotransmitters in the pathway for pain perception, thereby reducing the physical impact of pain.
We believe the Topical Spray Film Delivery Technology could provide a pathway for additional proprietary spray formulations, with strong adhesion and accessibility properties upon application, especially around joints and curved body surfaces.
(Note: Virpax Pharmaceuticals upsized its IPO at pricing on Feb. 16, 2021, to 1.8 million shares, up from 1.36 million, at $10, the low end of its $10-to-$12 range, to raise $18 million.)
|Address||1554 Paoli Pike, #279 West Chester, PA 19380|
|Phone Number||(484) 880-4588|
|View Prospectus:||Virpax Pharmaceuticals, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-4.33 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$18.0 mil|
|Manager / Joint Managers||ThinkEquity (a division of Fordham Financial Management)|
|Expected To Trade:||2/17/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|